NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION (INCLUDING THE UNITED STATES) WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.
Sativa Wellness Group Inc.
("Sativa" or "Sativa Wellness" the "Company" or the "Group")
4th February 2021
Sativa Wellness Group Announces Further Board Update
Further to the Company's news release dated January 29, 2021 regarding the Annual General and Special Meeting of the shareholders held on January 26, 2021 (the "Meeting"), each of Geremy Thomas and George Thomas have been appointed as directors, and Geremy Thomas has been appointed as Executive Chairman of the Board. Following the Meeting, Henry Lees-Buckley is no longer Chief Executive Officer of the Company effective February 3, 2021. In addition to his role as Executive Chairman, Geremy Thomas will act as the interim CEO until such time as the Board appoints a new CEO.
Each of Jonathan Wearing and Angus Kerr have resigned from the Board as of February 1, 2021, as Chairman of the Board of the Company, and as Non-Executive Director, respectively.
In addition, Joseph Colliver has resigned from the Board and as Chief Financial Officer effective February 2, 2021. Joseph Colliver has agreed to continue as Chief Financial Officer through his three-month notice period to support the strategic review of the Company and the appointment of his successor.
The Company wishes to thank all former directors and officers for their contribution to the Company. The Company will continue to evaluate new candidates to fill the vacancies left on the Board.
Clive Thomas Standish has been appointed as a Non-Executive Director effective February 3, 2021 to add strength to the Board. His career experience includes NM Rothschild and being a Director of the UBS AG Executive Board, which gives the Company significant additional strategic and capital markets strength at the Board level.
Further information on Clive Standish:
Clive Standish currently has an interest of 418,838 common shares in the Company, representing 0.14 % of the Company's issued share capital.
|
Current Directorships
|
Previous Directorships
|
|
Ardenside Aneus Pty Ltd
|
The Multifamily Housing Reit Limited
|
|
Exhall Pty Ltd
|
Multifamily Asset 1 Limited
|
|
|
Mentor Foundation UK
|
|
|
Ganymed Pty Ltd
|
Except as set out below, there is no further information regarding Clive Thomas Standish, aged 67, that is required to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Apex Rulebook.
Clive Standish's professional career began with N M Rothschild & Sons Ltd in London. In 1979 he was appointed a partner with Dominguez & Barry in Australia and became a member of the Melbourne Stock Exchange in 1980. He was the founding Executive Director at Dominguez Barry Samuel Montagu Limited and subsequently Head of Capital Markets and Managing Director until 1991 and then CEO of SBC and Warburg Dillon Read Australia.
In 1998 Clive Standish was appointed Chairman and CEO for Asia Pacific UBS AG and member of the Managing Board and subsequently member of the Group Executive Board. In 2003 he moved to Zurich as Group Chief Financial Officer UBS AG until 2007 when he retired from the Board of UBS AG.
Geremy Thomas, Executive Chairman, said: "I am pleased to be back at the helm. I will be focusing the business on activities that generate cash and profit and will be making cost reductions in other areas."
The directors of the Company accept responsibility for the contents of this announcement.
On behalf of the Board of Directors,
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|
a)
|
Name
|
Clive Thomas Standish
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial notification /Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Sativa Wellness Group Inc.
|
|
b)
|
LEI
|
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary shares of no par value in Sativa Wellness Group Inc.
Identification code (ISIN) for Sativa Wellness Group Inc. ordinary shares: CA80403E1043
|
|
b)
|
Nature of the transaction
|
Disclosure of Ordinary Shares and warrants
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
£0.04
|
418,838
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
19 /12/ 2019
|
|
f)
|
Place of the transaction
|
AQSE Growth Market
|
